Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 9/20 | 0.49 |
| ▸ | TP53 | P04637 | 5/20 | 0.47 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | LHCGR | P22888 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1001191 | 0.93 | ALDH1A1 (0.49) | MAPTTP53SHMT2ALDH1A1NPSR1 | |
| SCHEMBL998419 | 0.91 | MAPT (0.50) | MAPTTP53ALDH1A1KDM4ELHCGR | |
| SCHEMBL999190 | 0.91 | MAPT (0.50) | MAPTTP53SHMT2ALDH1A1KDM4E | |
| SCHEMBL997538 | 0.91 | MAPT (0.46) | MAPTTP53NPSR1LHCGRLMNA | |
| SCHEMBL997584 | 0.88 | TP53 (0.60) | MAPTTP53SHMT2ALDH1A1NPSR1 | |
| SCHEMBL998055 | 0.88 | ABCB1 (0.53) | MAPTTP53LHCGRLMNAPOLB | |
| SCHEMBL1000508 | 0.86 | TP53 (0.53) | MAPTTP53SHMT2ALDH1A1LHCGR | |
| SCHEMBL998361 | 0.86 | MAPT (0.62) | MAPTTP53ALDH1A1LHCGRLMNA | |
| SCHEMBL998517 | 0.85 | TP53 (0.53) | MAPTTP53SHMT2ALDH1A1KDM4E | |
| SCHEMBL995264 | 0.85 | POLB (0.51) | MAPTTP53SHMT2ALDH1A1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7872133-B2 | Tricyclic heterocycle compound | ONO PHARMACEUTICAL CO., LTD. (JP) | 2011-01-18 | — | — | US | disclosed |
| US-20060154944-A1 | Novel tricyclic heterocycle compound | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-07-13 | — | — | US | disclosed |
| EP-1637521-A1 | NOVEL TRICYCLIC HETEROCYCLE COMPOUND | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-03-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060154944-A1 | Novel tricyclic heterocycle compound | CYP11B1, CYP11B2, HCCS | MAPT 4705/4885TP53 945/4885SHMT2 579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.